Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipamorelin
- Development stage
- Phase 2
- Lead developer
- Helsinn Therapeutics
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
Ipamorelin is a synthetic pentapeptide and selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR, also known as GHSR-1a). It mimics the action of ghrelin by binding to GHSR in the brain and other tissues, thereby selectively stimulating the release of growth hormone (GH) from the pituitary gland[1][3][4][8]. Unlike some other GH secretagogues, ipamorelin does not significantly affect levels of prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), or cortisol[4]. Its selectivity for GH release makes it distinct among similar peptides. Ipamorelin was originally developed by Novo Nordisk and later investigated by Helsinn Therapeutics for postoperative ileus but development was discontinued due to lack of efficacy[4]. It has also been used off-label in performance enhancement settings.
- Other names
- ipamorelin
02
Targets
GHSR (Growth hormone secretagogue receptor)
Beyond the preview
Go deeper on ipamorelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipamorelin.